|
|
British Journal of Cancer (2006) 95, 153-158.
doi:10.1038/sj.bjc.6603258
Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids
G Francini1, R Petrioli1, A Montagnani2, A Cadirni2, S Campagna2, E Francini1 and S Gonnelli2
1Department of Human Pathology and Oncology, Medical Oncology Section, University of Siena, Siena, Italy
2Department of Metabolic and Endocrinological Science and Biochemistry, University of Siena, Siena, Italy
Correspondence to: Professor G Francini, E-mail: francini@unisi.it
Received 10 April 2006; revised 14 June 2006; accepted 14 June 2006
Recent studies have shown that administering the aromatase inhibitor exemestane after 2-3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment. Although many of the adverse effects associated with exemestane and tamoxifen have been analysed, there are no comparative data concerning body weight and body composition. The aim of this randomised study was to evaluate the longitudinal changes in body composition and lipid profiles in postmenopausal women switched from tamoxifen to exemestane. In total, 60 overweight or obese postmenopausal patients were enrolled. Their anthropometric data, body composition, including fat mass (FM) and fat-free mass (FFM), and lipid profiles, caloric intake and physical activity were assessed 1 week before randomisation, and 6 and 12 months later. In all, 55 patients (27 on tamoxifen and 28 on exemestane) completed the 1-year study period. Fat mass had significantly decreased by month 12 in the exemestane, but not in the tamoxifen group; the between-group difference was statistically significant (P<0.01). The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group; the between-group difference was statistically significant (P<0.05). Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05), and low-density lipoprotein cholesterol significantly increased (P<0.01) in the exemestane group at the end of the 1-year study period. Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2 years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body composition.
Keywords: body weight; exemestane; hormonal therapy; lipid; tamoxifen
back to top  |
| Article links | |
| ||
| ||
 | Send to a friend | |
 | Download PDF | |
| ||
| ||
| ||
 | Full text | |
| ||
| ||
| ||
 | Preceding article | |
 | Next article | |
 | Table of Contents | |
| ||
| ||
| ||
| ||
| ||
|
|
|
|
| |||
| Print ISSN: 0007-0920 | Online ISSN: 1532-1827 | © 2006 Cancer Research UK | ||
| |||
| Privacy Policy | |||